Laobaixing Pharmacy (603883) Fair Value & Analysis
Healthcare · CN · Market cap 9.7B CNY (≈ $1.4B) · ISIN CNE1000023Q8
What is Laobaixing Pharmacy really worth?
A solid business, but trading 27% above our fair value of ¥10.57.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price +7.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
- The price sits above our optimistic bull case: the favourable scenario is already priced in.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥10.70 – ¥40.21 · fair‑value band ¥7.92 – ¥13.21 · the ¥13.47 price screens above the ¥10.57 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Laobaixing Pharmacy (603883) currently trades at ¥13.47, while our model-based Fair Value estimate is ¥10.57, implying the stock looks roughly 27.4% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥51.60 per share, and 16 of the 26 models we run sit above the ¥13.47 price. Bear case: the Dividend Discount group reads lowest at ¥4.48, and 10 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Laobaixing Pharmacy generated revenue of 22.3B CNY at a net margin of 1.8%. Revenue grew 0.8% year over year. It earns a return on equity of 7.6%. Net debt stands at 8.0B CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥7.92 (bear case) to ¥13.21 (bull case); at ¥13.47, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −22%, 603883 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.0744 per share, which is 0.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (¥51.60) versus Dividend Discount (¥4.48). Highest evidence: FCF DCF (76).
Notify me when 603883 reaches fair value
Put 603883 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other.
Full company description
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; E-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products. In addition, it provides business, information technology consulting, technical, pharmaceutical consulting, clinic, and medical services. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Laobaixing Pharmacy reported revenue of 22.2B CNY in FY2025 versus 15.7B CNY in FY2021, a compound +9.1%/yr. Reported net income was 382M CNY in FY2025, compounding −13.1%/yr from FY2021.
of which total revenue +20.8 % · buybacks/dilution −6.2 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
603883 screens 27% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
| Luyan Pharma Co 002788 | ¥10.96 | ¥15.91 | +45% |
Compare Laobaixing Pharmacy with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Laobaixing Pharmacy (603883) overvalued or undervalued?
What is the fair value of 603883?
What is the quality score of 603883?
What is the revenue of Laobaixing Pharmacy (603883)?
What is the net profit margin of 603883?
Does Laobaixing Pharmacy pay a dividend?
Watch Laobaixing Pharmacy in the live analysis
One click puts Laobaixing Pharmacy on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.